In search of a cure: Upstart Missoula biotech company Inimmune on the cutting edge of science

In a collection of small laboratories filled with glass beakers, liquid compounds and deep freezers, scientists with the upstart Missoula biotech firm Inimmune http://inimmune.com/ are looking to cure allergies, infectious diseases and cancer.

With a strong portfolio of drug candidates and a seasoned team of chemists, the scientists with Inimmune like their chances of getting a new drug to clinical trial within the next five years.

"Ideally, in 10 years we’ll have one or more products possibly in Phase 3 clinical trials," said Jay Evans, president and CEO of Inimmune. "In an ideal world, we’ll be on the doorstep of launching a potential cure for either food or seasonal allergies that could be life changing to lots of people."

"We have team members who had been there for over 20 years," said Evans. "The last thing we wanted to do was uproot their families and move them to Maryland. We began exploring options with GSK and devised a plan where we could start a company here in Missoula with the assistance of GSK."

"The potential is huge," Evans said. "When you talk about markets like allergy and autoimmunity, really the the sky’s the limit. Hopefully ours will be a model for university professors and others to start a biotech here in Montana. It’s a great place to live and do that kind of work."

By Martin Kidston

Full Story: http://www.missoulacurrent.com/headline/2016/08/search-cure-upstart-biotech-company-cutting-edge-science/